YM 511

Known as: YM-511, YM511 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2007
012319952007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent… (More)
Is this relevant?
2005
2005
The role of aromatase inhibitors in the treatment of hormone-dependent breast cancer is well established. However, it is now… (More)
Is this relevant?
2003
2003
Aromatase inhibitors in clinical use block the biosynthesis of estrogens. Hydrolysis of estrone 3-sulfate by steroid sulfatase is… (More)
Is this relevant?
2003
2003
BACKGROUND A phase II study of a non-steroidal selective aromatase inhibitor, YM511, 4-[N-bromobenzyl]-N-(4H-1,2,4-triazol-4-yl… (More)
Is this relevant?
1997
1997
Estrogen deprivation therapy effectively prevents progress of endometriosis but the precise mechanism by which estrogen… (More)
Is this relevant?
1997
1997
A series of [(4-bromobenzyl)(4-cyanophenyl)amino]azoles and their azine analogs, which have the side chain of the selective… (More)
Is this relevant?
1997
1997
In order to study the potency of the 5-aminopyrimidine skeleton as an aromatase inhibitor, we synthesized various N,N… (More)
Is this relevant?
1996
1996
Various 4-N-substituted amino-4H-1,2,4-triazole derivatives were synthesized and evaluated for aromatase-inhibitory activity (in… (More)
Is this relevant?
1996
1996
The proliferation of MCF-7, human breast cancer cell line, was stimulated by testosterone and estradiol. The aromatase activity… (More)
Is this relevant?
1995
1995
YM511 inhibited aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s: 0.4 and 0.12 nM… (More)
Is this relevant?